Table 1 Baseline characteristics of included patients in the HEPAR-PLuS trial
N (%) | |
|---|---|
Number of patients | 31 |
Age—Median (IQR) | 65.1 (57.6–70.2) |
Gender | |
Male | 23 (74.2%) |
Female | 8 (25.8%) |
Origin of tumor | |
Pancreas | 10 (32.3%) |
Small intestine | 8 (25.8%) |
Colorectal | 4 (12.9%) |
Lung | 3 (9.7%) |
Unknown primary | 6 (19.4%) |
WHO Grade | |
1 | 12 (38.7%) |
2 | 19 (61.3%) |
Weeks since final cycle PRRT—Median (IQR) | 12.7 (9.7–15.8) |
ECOG status | |
0 | 17 (54.8%) |
1 | 13 (41.9%) |
2 | 1 (3.2%) |
Total liver dose in Gy—Median (IQR)a | 46.4 (41.2–55.1) |
Tumor burden in %—Median (IQR) | 6.9% (3.1–22.5%) |
Extrahepatic disease | |
Absent | 11 (35.5%) |
Lymph nodes | 5 (16.1%) |
Visceral | 6 (19.4%) |
Lymph nodes and visceral | 9 (29.0%) |
Baseline NLR—Median (IQR) | 4.3 (3.6–5.7) |
Baseline TLR—Median (IQR) | 238 (176–308) |